The underlying defects in Angelman syndrome (AS) and autism spectrum disorder (ASD) may be in part due to basic defects in synaptic plasticity and function. In some individuals serotonin reuptake inhibitors, which decrease pre-synaptic re-uptake of serotonin, can ameliorate symptoms, as can resperidone, which blocks both dopamine and serotonin receptors. Loss of maternal UBE3A expression causes AS, while maternal duplications of chromosome 15q11.2-q13 that include the UBE3A gene cause ASD, implicating the maternally expressed UBE3A gene in the ASD phenotype. In a Drosophila screen for proteins regulated by UBE3A, we identified a key regulator of monoamine synthesis, the gene Punch, or GCH1, encoding the enzyme GTP cyclohydrolase I. Here we show that Dube3a, the fly UBE3A orthologue, regulates Punch/GCH1 in the fly brain. Over-expression of Dube3a elevates tetrahydrobiopterin (THB), the rate-limiting cofactor in monoamine synthesis while loss of Dube3a has the opposite effect. The fluctuations in dopamine levels were associated with hyper-and hypoactivity, respectively, in flies. We show that changes in Punch/GCH1 and dopamine levels do not depend on the ubiquitin ligase catalytic domain of Dube3a. In addition, both wild type Dube3a and a ubiquitination-defective Dube3a-C/A form were found at high levels in nuclear fractions and appear to be poly-ubiquitinated in vivo by endogenous Dube3a. We propose that the transcriptional co-activation function of Dube3a may regulate GCH1 activity in the brain. These results provide a connection between monoamine synthesis (dopamine/serotonin) and Dube3a expression that may explain why some individuals with ASD or AS respond better to selective serotonin reuptake inhibitors than others.
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Introduction
The regulation of neurotransmitters like dopamine and serotonin in the brain is critical for proper synaptic function as well as plasticity. These neurotransmitters may be inappropriately regulated in the brains of autistic individuals accounting for at least some of the synaptic stability defects observed in autism (Makkonen et al., 2008) . Although the underlying genetic heterogeneity of idiopathic autism has complicated the analysis of neurotransmitter levels, it has become apparent that at least some individuals with autism have altered tetrahydrobiopterin (THB) levels in cerebrospinal fluid (Tani et al., 1994) . THB is a regulatory cofactor for the synthesis of monoamines including both dopamine and serotonin, neurotransmitters that have been linked to many of the behavioral traits manifested in ASD. Resperidone, an atypical neuroleptic that blocks dopamine and serotonin receptors has been widely employed to ameliorate monoamine-related behaviors in autistic individuals (c.f., Canitano and Scandurra, 2008) . Treatment of the anxiety and hyperactivity associated with autism often involves the use of selective serotonin reuptake inhibitors (SSRIs), which inhibit the presynaptic re-uptake of serotonin thereby increasing postsynaptic activation (Kolevzon et al., 2006) . Consistent with mounting evidence of monoamine variation in ASD are reports of haplotype associations in monoamine-related genes. For example, Hettinger et al. (2008) reported over-transmission in ASD families of two D1 dopamine receptor haplotypes (Hettinger et al., 2008) . Thus, the improper regulation of synaptic monoamine levels may be a key aspect of autism pathogenesis.
The most common cytogenetic abnormalities detected in autistic individuals are maternally derived DNA duplications of the 15q11.2-q13 region, also known as the Prader-Willi/Angelman syndrome critical region (reviewed in (Hogart et al., 2010) . The primary candidate gene in this region, UBE3A, encodes an E3 ubiquitin ligase Neurobiology of Disease 41 (2011) 669-677 
